From www.bloodjournal.org by guest on April 13, 2015. For personal use only.

Blood First Edition Paper, prepublished online March 25, 2015; DOI 10.1182/blood-2014-09-551887

Title: How I treat priapism Authors: Uzoma A. Anele,1 Brian V. Le,1 Linda M. S. Resar,2,3,4 and Arthur L. Burnett1 Affiliations: 1 The James Buchanan Brady Urological Institute and Department of Urology, The Johns Hopkins University School of Medicine, Baltimore, MD 20817 2 Division of Hematology, Department of Medicine, 3Department of Oncology, and 4Institute for Cellular Engineering, The Johns Hopkins University School of Medicine, Baltimore, MD 20817 Correspondence: Arthur L. Burnett, MD, MBA Address: The Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD 21287-2101, USA Phone: 410-614-3986 Fax: 410-614-3695 Email: [email protected] Additional Author Emails: Uzoma A. Anele [email protected] Brian V. Le [email protected] Linda M. S. Resar [email protected] Conflict of Interest: The authors declare that they have no conflicts of interest.

Running Head: HOW I TREAT PRIAPISM

Word Count: 3,741/4,000

1 Copyright © 2015 American Society of Hematology

From www.bloodjournal.org by guest on April 13, 2015. For personal use only.

Abstract Priapism is a disorder of persistent penile erection unrelated to sexual interest or desire. This pathologic condition, specifically the ischemic variant, is often associated with devastating complications, notably erectile dysfunction. Because priapism demonstrates high prevalence in patients with hematological disorders, most commonly sickle cell disease (SCD), there is significant concern for its sequelae in this affected population. Thus, timely diagnosis and management are critical for the prevention or at least reduction of cavernosal tissue ischemia and potential damage consequent to each episode. Current guidelines and management strategies focus primarily on reactive treatments. However, an increasing understanding of the molecular pathophysiology of SCD-associated priapism has led to the identification of new potential therapeutic targets. Future agents are being developed and explored for use in the prevention of priapism.

Introduction Priapism is an uncommon pathologic condition involving prolonged penile erection in the absence of sexual arousal or desire.1,2 The term is derived from Priapus, a Greek god of fertility renowned for his large phallus.3,4 Incidence rates of 1.5 per 100,000 person-years have been estimated among the general population.5 The ischemic sub-type is common in sickle cell disease (SCD) with prevalence rates of up to 40%.6,7 In fact, SCD is an etiologic factor in approximately 23% of adult and 63% of pediatric cases.8 Several previous cohort studies have demonstrated high prevalence rates ranging from 27.5% to 42% in SCD, with up to 89% estimated to experience priapism by 20 years of age.6,7,9 Ischemic priapism is associated with devastating complications including erectile tissue necrosis and fibrosis.1,2 When episodes are unremitting, increasingly invasive options are employed in an attempt to prevent worsening tissue damage and preserve erectile function, or simply provide palliative care when erectile function can no longer be preserved. Here, we present an algorithm for identifying and managing ischemic priapism in SCD as well as the rationale behind various treatments.

2

From www.bloodjournal.org by guest on April 13, 2015. For personal use only.

Case R. J. was a 22 year old African American man who presented to the emergency room (ER) with a painful erection lasting approximately 6 hours. He had been in his usual state of health until he finished mowing the lawn and noticed gradual development of an erection. He tried over-the-counter analgesics and masturbation without improvement. He reported previous episodes requiring several ER visits in the past few months, which resolved spontaneously with supplemental oxygen. There was no penile or pelvic trauma, although he reported a family history of SCD. On examination, he had a tender, engorged phallus. There was no hematoma, mucosal pallor or scleral icterus; remaining examination was unremarkable. He received supplemental oxygen and morphine for pain. Corporal aspiration and blood-gas analysis were consistent with ischemia. Further corporal aspiration and irrigation were performed without improvement. Phenylephrine injections ultimately led to penile detumescence. Hemoglobin variant analysis using high performance liquid chromatography showed hemoglobin SS. He was then monitored overnight until discharged the next day.

Nitric Oxide Role in Normal Erection Physiology Penile erection involves a complex coordination of vasorelaxing and vasoconstricting signals from parasympathetic and sympathetic inputs10, respectively, in order to control blood flow within the penis and allow for its engorgement.11 In its basal state, vascular and smooth muscle tone is maintained by vasoconstrictive factors10, allowing the penis to remain in a flaccid state for nearly 23 hours each day.12 Inhibition of this contractile state can occur with genital stimulation, psychosexual excitement, or rapideye movement sleep.13 Upon stimulation, penile erection is facilitated by smooth muscle relaxation, allowing for increased arterial blood flow and trabecular cavernosal tissue distension.14 This distension reduces venous outflow, thus permitting and sustaining penile engorgement.15 Recent investigations into molecular mechanisms underlying penile erection have revealed nitric oxide (NO) signaling as a critical component in normal erections.16,17 Erectile stimulation involves vascular and neurogenic pathways regulated by endothelial and neuronal isoforms of the NO synthase (NOS) enzyme, the primary mediator

3

From www.bloodjournal.org by guest on April 13, 2015. For personal use only.

of NO synthesis. Upon activation, endothelial NOS (eNOS) and neuronal NOS (nNOS) utilize L-arginine to generate NO, which diffuses locally into smooth muscle cells to initiate vasodilation through activation of the downstream cyclic guanosine monophosphate (cGMP) pathway (Figure 1).13,18 Termination of the erectile response occurs when phosphodiesterase type 5 (PDE5) hydrolyzes cGMP, inactivating the second messenger nucleotide19 and returning the penis to its flaccid state (Figure 1).

Priapism Classification and Etiology Ischemic Priapism Ischemic priapism, also known as low-flow or veno-occlusive priapism, comprises over 95% of presentations20 and is the variant most commonly observed in patients with SCD. Ischemic priapism is associated with decreased or absent cavernous blood flow, corporal rigidity, and pain.2 It represents a compartment-like syndrome characterized by increased pressure within the enclosed cavernosal space and compressed circulation.21 Consequently, ischemic priapism is a medical emergency with potentially profound sequelae if left untreated. Histopathologic studies show time-dependent erectile tissue damage22 with irreversible corporal damage occurring in episodes lasting >6 hours (major priapism).23 Thus, patients are advised to seek immediate medical care with major episodes.2 Beyond 24 hours, tissue necrosis and fibroblast proliferation result22,24 and can lead to erectile dysfunction (ED), with estimated rates as high as 90% from episodes lasting >24 hours.20 Priapism can also lead to significant psychological and social sequelae.25 Diverse etiologies for priapism have been described, including neurologic conditions, pharmacologic exposures, trauma and idiopathic presentations (Table 1). Hematologic disorders, such as SCD, glucose-6-phosphate deficiency, and hereditary spherocytosis, have been implicated in ischemic priapism.7,26,27 While SCD itself is a key risk factor, the presence of other SCD complications, including ischemic stroke, leg ulcers, and vaso-occlusive episodes, have been associated with priapism.28 To identify SCD patients at risk for priapism, hemolytic biomarkers were investigated and patients with a history of priapism have significantly lower hemoglobins and higher lactate dehydrogenase as compared

4

From www.bloodjournal.org by guest on April 13, 2015. For personal use only.

to SCD patients without priapism.29,30 Moreover, polymorphisms in genes that regulate vascular tone, endothelial NO metabolism, coagulation, cell adhesion, and cell hydration have been linked to priapism in SCD.31,32 However, parameters are not readily available and further studies are needed to validate these findings.11

Recurrent Ischemic Priapism Recurrent ischemic priapism (RIP), also known as stuttering priapism, involves repeated episodes of ischemic priapism with intervening periods of detumescence.2 The natural history of RIP is heterogeneous; most episodes are transient and self-remitting, often occurring during sleep and lasting for 70% of SCD patients with a history of severe priapism have a history of RIP.6 Despite the relatively shorter duration, RIP is associated with a risk of cavernosal fibrotic injury and may lead to ED in 29-48% in patients.6,7,33

Non-Ischemic Priapism Non-ischemic (also known as high-flow or arterial) priapism is a non-emergent variant of persistent erections caused by unregulated cavernous arterial inflow and occurs in less than 5% of observed clinical presentations.2,20,34 This variant is typically consequent to disruptions of the cavernous arterial supply involving mechanisms of injury including arterial aneurysm, arterio-venous fistula, iatrogenic needle injury, or pelvic trauma resulting in arteriolar-sinusoidal fistula formation.11,20 Following trauma, fistula formation allows blood from the cavernous artery to enter the lacunar spaces rather than the helicine arteries, resulting in unregulated penile engorgement.35 Contrary to these “classic” mechanisms of non-ischemic priapism, several reports have identified this phenomenon in the absence of anatomical abnormalities and particularly in the presence of SCD.8,36 This may suggest a role of hematologic disorders in development of this characteristic hyperemic environment, although the

5

From www.bloodjournal.org by guest on April 13, 2015. For personal use only.

underlying mechanism is unknown.37 In this variant, the corpora are usually tumescent, typically lacking rigidity and pain,2 and episodes may spontaneously resolve with little or no complications.11

Pathophysiology of RIP Until recently, the classic vaso-occlusive paradigms of erythrocyte sludging within vascular spaces associated with SCD fostered the belief that vascular stasis and increased viscosity in the penis were the primary causes of this disorder.38 Emerging evidence has uncovered a likely molecular basis underlying RIP in SCD involving decreased NO bioavailability. Studies with mouse models of SCD which exhibit priapism found aberrations in NO signaling as a primary mechanism underlying priapism.39 This and other mouse models of priapism exhibit decreased PDE5 production and basally lower cGMP levels.39 cGMP is reduced secondary to a chronic decrease in production of endothelium-derived NO, which results from vasculopathic damage in SCD.39-42 Hemolysis also serves as a basis for decreased NO because free hemoglobin avidly scavenges intravascular NO. Arginase is also released from hemolyzed red cells, which reduces L-arginine, a substrate for NO production. Furthermore, excessive reactive oxygen species (ROS) production, a chronic state in SCD, also impairs endothelium-derived NO formation and function.43-45 With neurologic erectogenic stimulation, which can occur with sexual activity or sleep, neuronally-derived NO production increases cGMP levels to promote cavernosal relaxation. However, down-regulation of basal PDE5 levels results in an inability to adequately terminate the resulting downstream vasodilatory effects of heightened cGMP release (Figure 1). Thus, the erectile response is uncontrolled, and the penis becomes priapic. Additional signaling pathways involving RhoA/ROCK, adenosine, and opiorphin pathways have been implicated in the molecular pathophysiology of priapism.13,46-48

Diagnosis

6

From www.bloodjournal.org by guest on April 13, 2015. For personal use only.

The goal of initial assessment lies in distinguishing between the ischemic and non-ischemic variants. An appropriate evaluation is essential because ischemic priapism is a urologic emergency. As such, history, physical examination, laboratory testing, and imaging are useful tools in determining both the etiology and subsequent treatment modality.

History and Physical Examination Prolonged pain is an important predictor of ischemic priapism. Clinical histories should also include duration, circumstances associated with onset, co-morbid conditions (SCD or coagulation disorders), history of previous episodes, pharmacotherapy (erectogenic, psychoactive or recreational drugs), alleviating maneuvers, prior treatments, and previous erectile function. Physical examination should include an evaluation of the phallus by inspection and palpation to determine the extent of tumescence, as well as overall for signs of trauma, hematological malignancy, or evidence of hemolytic disease. Unlike non-ischemic priapism, ischemic priapism is characterized by the presence of rigidity and tenderness of the cavernosal bodies with absence of glans/penis involvement.

Laboratory Testing Corporal aspiration and blood gas analysis from the priapic penis is crucial in diagnosing ischemic priapism.2 The presence of acidosis, hypoxia, and hypercapnia (pH72 hrs.

Surgical Management Surgical management of ischemic priapism is customarily considered if first-line therapies fail to resolve the priapism episode, or if the clinical history and review of prior therapies suggest that surgical management should be offered initially. The International Society of Sexual Medicine (ISSM) recommends that penile shunting procedures be considered for priapism episodes lasting >72 hrs, as “first-line” therapies are less likely to be effective. Prior to surgical intervention, it is paramount that a thorough, well-documented discussion occurs between the surgeon and patient, as this is a condition with a disproportionate level of medical-legal consequences. In addition to discussing the indications, risks, and benefits of the procedure, the patient should understand that the duration of priapism and resultant injury to corporal tissue, including necrosis and fibrosis, place him at high risk of permanent ED despite surgical intervention. The objective of shunting procedures is to establish a communication between the sinusoids of the corpora cavernosa and the glans, corpus spongiosum or vein for drainage to allow egress of blood. This involves making a window through the tunica albuginea. In general, the selection of shunting procedures is largely dependent upon the familiarity and comfort-level of the practitioner. The distal shunt, a corpora-glanular shunt, is generally preferred because it is easier to perform, and has lower complication rates when compared to proximal shunts. There are several variants from percutaneous to open approaches,90-96 which can be followed by penile prosthesis implantation. Proximal shunting has been reserved for priapism episodes refractory to distal shunting because it is a more complex procedure with higher complication rates. Proximal shunting involves creating a window between the corpus cavernosum and corpus spongiosum at the level of the crura typically through a perineal or transscrotal approach or utilization of venous anastomoses to shunt blood out of the corpora.97-99 Shunting procedures

12

From www.bloodjournal.org by guest on April 13, 2015. For personal use only.

carry inherent risks of complications such as ED, infection, urethra-cavernous fistulas, cavernositis and urethral strictures.100 Complications that result from such shunting procedures should be distinguished from the risk of the disease, such as ED or changes in sensation. Complete detumescence may not be achieved due to turgor and edema. Penile color duplex ultrasonography can be used to confirm return of cavernosal blood flow. High flow priapism has been reported to occur following shunting with return of heightened blood flow in the cavernosal arteries as demonstrated by ultrasonography.101,102 Early penile prosthesis implantation is a third option, particularly in adult patients, that may be selected based on the likelihood of permanent ED. Priapism episodes lasting continuously for >36 hrs are almost invariably associated with permanent ED. This time frame may be altered as patients undergo treatments that achieve partial restoration of blood flow, but later fail. Thus, some urologists recommend 72 hrs from the initial event as a cutoff for strongly considering early penile prosthesis to reduce fibrosis and maintain penile length.23 Recommendations exist for penile prosthesis surgery in cases of refractory RIP as well. However, these uses are controversial. For major priapism, it may be difficult to obtain a well-deliberated consent from a distressed patient as well as timely approval for insurance costcoverage.103 Ultimately, the decision for penile prosthesis surgery must be reached jointly with the patient based on goals and risk/benefit determinations. The principles of priapism management are largely similar in both pediatric and adult populations, with technical exceptions relating to corporal aspiration volumes, sympathomimetic dosing, and anesthesia considerations.104

Future Perspectives Adequate prophylactic management strategies for RIP are lacking. Recent studies identifying multiple complementary signaling pathways underlying the pathophysiology of RIP offer new and exciting therapeutic approaches for RIP prevention and management. Recognition of the roles of NO,

13

From www.bloodjournal.org by guest on April 13, 2015. For personal use only.

RhoA/ROCK, adenosine, and opiorphins may lead to the development of future agents potentially targeting these molecular effectors.39,46-48,105,106 Strategies involving the use of PDE5 inhibitors to correct the underlying aberrations in NO balance have met with some success, as well as challenges regarding cost and patient adherence.51-53,107 Preclinical investigations in animal models of SCD have uncovered alternative methods of restoring NO balance through the use of sustained NO-releasing compounds.108 The success of orinthine decarboxylase inhibitors and adenosine deaminase enzyme replacement in animal models as modulators of opiorphin and adenosine pathways, respectively, have also showed potential promise as plausible therapies in reducing the risk of priapism recurrence.47,109,110 The management of priapism should involve a multidisciplinary approach. Patient education and clinical cooperation are necessary in addressing the deficiencies created by our current health care policy. 111

The higher prevalence of priapism among patients with hematologic and coagulation disorders requires

comprehensive management strategies engaging hematologic and urologic care providers. Collaborative efforts within the medical community will be essential to advance treatment strategies.

Acknowledgments U.A.A. and B.V.L. performed literature searches and prepared the first draft of the manuscript; and L.M.S.R., and A.L.B. reviewed, edited, and approved the final manuscript. The authors declare that there are no conflicts of interest.

14

From www.bloodjournal.org by guest on April 13, 2015. For personal use only.

References

1. Berger R, Billups K, Brock G, et al. Report of the American Foundation for Urologic Disease (AFUD) Thought Leader Panel for evaluation and treatment of priapism. Int J Impot Res. 2001;13 Suppl 5:S39-43. 2. Montague DK, Jarow J, Broderick GA, et al. American Urological Association guideline on the management of priapism. J Urol. 2003;170(4 Pt 1):1318-1324. 3. Morrison BF, Burnett AL. Priapism in hematological and coagulative disorders: an update. Nat Rev Urol. 2011;8(4):223-230. 4. Burnett AL, Bivalacqua TJ. Priapism: current principles and practice. Urol Clin North Am. 2007;34(4):631-642, viii. 5. Eland IA, van der Lei J, Stricker BH, Sturkenboom MJ. Incidence of priapism in the general population. Urology. 2001;57(5):970-972. 6. Adeyoju AB, Olujohungbe AB, Morris J, et al. Priapism in sickle-cell disease; incidence, risk factors and complications - an international multicentre study. BJU Int. 2002;90(9):898-902. 7. Emond AM, Holman R, Hayes RJ, Serjeant GR. Priapism and impotence in homozygous sickle cell disease. Arch Intern Med. 1980;140(11):1434-1437. 8. Nelson JH, 3rd, Winter CC. Priapism: evolution of management in 48 patients in a 22-year series. J Urol. 1977;117(4):455-458. 9. Mantadakis E, Cavender JD, Rogers ZR, Ewalt DH, Buchanan GR. Prevalence of priapism in children and adolescents with sickle cell anemia. J Pediatr Hematol Oncol. 1999;21(6):518-522. 10. Andersson KE. Pharmacology of penile erection. Pharmacol Rev. 2001;53(3):417-450. 11. Olujohungbe A, Burnett AL. How I manage priapism due to sickle cell disease. Br J Haematol. 2013;160(6):754-765. 12. Christ GJ, Richards S, Winkler A. Integrative erectile biology: the role of signal transduction and cell-to-cell communication in coordinating corporal smooth muscle tone and penile erection. Int J Impot Res. 1997;9(2):69-84. 13. Bivalacqua TJ, Musicki B, Kutlu O, Burnett AL. New insights into the pathophysiology of sickle cell disease-associated priapism. J Sex Med. 2012;9(1):79-87. 14. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev. 1995;75(1):191-236. 15. Fournier GR, Jr., Juenemann KP, Lue TF, Tanagho EA. Mechanisms of venous occlusion during canine penile erection: an anatomic demonstration. J Urol. 1987;137(1):163-167. 16. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH. Nitric oxide: a physiologic mediator of penile erection. Science. 1992;257(5068):401-403. 17. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med. 1992;326(2):90-94. 18. Ignarro LJ. Haem-dependent activation of guanylate cyclase and cyclic GMP formation by endogenous nitric oxide: a unique transduction mechanism for transcellular signaling. Pharmacol Toxicol . 1990;67(1):1-7. 19. Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem. 1999;274(20):13729-13732. 20. Broderick GA. Priapism and sickle-cell anemia: diagnosis and nonsurgical therapy. J Sex Med. 2012;9(1):88-103. 21. Song PH, Moon KH. Priapism: current updates in clinical management. Korean J Urol. 2013;54(12):816-823. 22. Spycher MA, Hauri D. The ultrastructure of the erectile tissue in priapism. J Urol. 1986;135(1):142-147. 15

From www.bloodjournal.org by guest on April 13, 2015. For personal use only.

23. Ralph DJ, Garaffa G, Muneer A, et al. The immediate insertion of a penile prosthesis for acute ischaemic priapism. Eur Urol. 2009;56(6):1033-1038. 24. Kovac JR, Mak SK, Garcia MM, Lue TF. A pathophysiology-based approach to the management of early priapism. Asian J Androl. 2013;15(1):20-26. 25. Addis G, Spector R, Shaw E, Musumadi L, Dhanda C. The physical, social and psychological impact of priapism on adult males with sickle cell disorder. Chronic Illn. 2007;3(2):145-154. 26. Burnett AL, Bivalacqua TJ. Glucose-6-phosphate dehydrogenase deficiency: an etiology for idiopathic priapism? J Sex Med. 2008;5(1):237-240. 27. Prabhakaran K, Jacobs BL, Smaldone MC, Franks ME. Stuttering priapism associated with hereditary spherocytosis. Can J Urol. 2007;14(5):3702-3704. 28. Kato GJ. Priapism in sickle-cell disease: a hematologist's perspective. J Sex Med. 2012;9(1):70-78. 29. Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH. Hemolysis-associated priapism in sickle cell disease. Blood. 2005;106(9):3264-3267. 30. Kato GJ, McGowan V, Machado RF, et al. Lactate dehydrogenase as a biomarker of hemolysisassociated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sickle cell disease. Blood. 2006;107(6):2279-2285. 31. Elliott L, Ashley-Koch AE, De Castro L, et al. Genetic polymorphisms associated with priapism in sickle cell disease. Br J Haematol. 2007;137(3):262-267. 32. Nolan VG, Baldwin C, Ma Q, et al. Association of single nucleotide polymorphisms in klotho with priapism in sickle cell anaemia. Br J Haematol. 2005;128(2):266-272. 33. Anele UA, Burnett AL. Erectile Dysfunction after Sickle Cell Disease-Associated Recurrent Ischemic Priapism: Profile and Risk Factors. J Sex Med. 2015. 34. Burnett AL, Bivalacqua TJ. Priapism: new concepts in medical and surgical management. Urol Clin North Am. 2011;38(2):185-194. 35. Yuan J, Desouza R, Westney OL, Wang R. Insights of priapism mechanism and rationale treatment for recurrent priapism. Asian J Androl. 2008;10(1):88-101. 36. Ramos CE, Park JS, Ritchey ML, Benson GS. High flow priapism associated with sickle cell disease. J Urol. 1995;153(5):1619-1621. 37. Melman A, Serels S. Priapism. Int J Impot Res. 2000;12 Suppl 4:S133-139. 38. Hinman F, Jr. Priapism; reasons for failure of therapy. J Urol. 1960;83:420-428. 39. Champion HC, Bivalacqua TJ, Takimoto E, Kass DA, Burnett AL. Phosphodiesterase-5A dysregulation in penile erectile tissue is a mechanism of priapism. Proc Natl Acad Sci U S A. 2005;102(5):1661-1666. 40. Bivalacqua TJ, Liu T, Musicki B, Champion HC, Burnett AL. Endothelial nitric oxide synthase keeps erection regulatory function balance in the penis. Eur Urol. 2007;51(6):1732-1740. 41. Bivalacqua TJ, Musicki B, Hsu LL, Gladwin MT, Burnett AL, Champion HC. Establishment of a transgenic sickle-cell mouse model to study the pathophysiology of priapism. J Sex Med. 2009;6(9):24942504. 42. Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol. 2009;84(9):618-625. 43. Houston M, Estevez A, Chumley P, et al. Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J Biol Chem. 1999;274(8):4985-4994. 44. Aslan M, Ryan TM, Adler B, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci U S A. 2001;98(26):15215-15220. 45. Wood KC, Granger DN. Sickle cell disease: role of reactive oxygen and nitrogen metabolites. Clin Exp Pharmacol Physiol. 2007;34(9):926-932. 16

From www.bloodjournal.org by guest on April 13, 2015. For personal use only.

46. Bivalacqua TJ, Ross AE, Strong TD, et al. Attenuated RhoA/Rho-kinase signaling in penis of transgenic sickle cell mice. Urology. 2010;76(2):510 e517-512. 47. Kanika ND, Tar M, Tong Y, Kuppam DS, Melman A, Davies KP. The mechanism of opiorphininduced experimental priapism in rats involves activation of the polyamine synthetic pathway. Am J Physiol Cell Physiol. 2009;297(4):C916-927. 48. Mi T, Abbasi S, Zhang H, et al. Excess adenosine in murine penile erectile tissues contributes to priapism via A2B adenosine receptor signaling. J Clin Invest. 2008;118(4):1491-1501. 49. Bennett N, Mulhall J. Sickle cell disease status and outcomes of African-American men presenting with priapism. J Sex Med. 2008;5(5):1244-1250. 50. LeRoy TJ, Broderick GA. Doppler blood flow analysis of erectile function: who, when, and how. Urol Clin North Am. 2011;38(2):147-154. 51. Burnett AL, Anele UA, Trueheart IN, Strouse JJ, Casella JF. Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease. Am J Med. 2014;127(7):664668. 52. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Feasibility of the use of phosphodiesterase type 5 inhibitors in a pharmacologic prevention program for recurrent priapism. J Sex Med. 2006;3(6):1077-1084. 53. Burnett AL, Bivalacqua TJ, Champion HC, Musicki B. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism. Urology. 2006;67(5):1043-1048. 54. Machado RF, Barst RJ, Yovetich NA, et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood. 2011;118(4):855-864. 55. Olujohungbe AB, Adeyoju A, Yardumian A, et al. A prospective diary study of stuttering priapism in adolescents and young men with sickle cell anemia: report of an international randomized control trial--the priapism in sickle cell study. J Androl. 2011;32(4):375-382. 56. Abern MR, Levine LA. Ketoconazole and prednisone to prevent recurrent ischemic priapism. J Urol. 2009;182(4):1401-1406. 57. Dahm P, Rao DS, Donatucci CF. Antiandrogens in the treatment of priapism. Urology. 2002;59(1):138. 58. Serjeant GR, de Ceulaer K, Maude GH. Stilboestrol and stuttering priapism in homozygous sicklecell disease. Lancet. 1985;2(8467):1274-1276. 59. Shamloul R, el Nashaar A. Idiopathic stuttering priapism treated successfully with low-dose ethinyl estradiol: a single case report. J Sex Med. 2005;2(5):732-734. 60. Steinberg J, Eyre RC. Management of recurrent priapism with epinephrine self-injection and gonadotropin-releasing hormone analogue. J Urol. 1995;153(1):152-153. 61. Hoeh MP, Levine LA. Prevention of recurrent ischemic priapism with ketoconazole: evolution of a treatment protocol and patient outcomes. J Sex Med. 2014;11(1):197-204. 62. Yamashita N, Hisasue S, Kato R, et al. Idiopathic stuttering priapism: recovery of detumescence mechanism with temporal use of antiandrogen. Urology. 2004;63(6):1182-1184. 63. Morrison BF, Burnett AL. Stuttering priapism: insights into pathogenesis and management. Curr Urol Rep. 2012;13(4):268-276. 64. Goetz T, Burnett AL. Prostate cancer risk after anti-androgen treatment for priapism. Int Urol Nephrol. 2014;46(4):757-760. 65. Anele UA, Morrison BF, Burnett AL. Molecular Pathophysiology of Priapism: Emerging Targets. Curr Drug Targets. 2014. 66. Morrison BF, Reid M, Madden W, Burnett AL. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report. Andrology. 2013;1(4):576-582. 17

From www.bloodjournal.org by guest on April 13, 2015. For personal use only.

67. Burnett AL, Kan-Dobrosky N, Miller MG. Testosterone replacement with 1% testosterone gel and priapism: no definite risk relationship. J Sex Med. 2013;10(4):1151-1161. 68. Morrison BF, Anele UA, Reid ME, Madden WA, Feng Z, Burnett AL. Is testosterone deficiency a possible risk factor for priapism associated with sickle-cell disease? Int Urol Nephrol. 2015;47(1):47-52. 69. Traish A, Kim N. The physiological role of androgens in penile erection: regulation of corpus cavernosum structure and function. J Sex Med. 2005;2(6):759-770. 70. Morelli A, Filippi S, Mancina R, et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology. 2004;145(5):2253-2263. 71. Zvara P, Sioufi R, Schipper HM, Begin LR, Brock GB. Nitric oxide mediated erectile activity is a testosterone dependent event: a rat erection model. Int J Impot Res. 1995;7(4):209-219. 72. Al Jam'a AH, Al Dabbous IA. Hydroxyurea in the treatment of sickle cell associated priapism. J Urol. 1998;159(5):1642. 73. Saad ST, Lajolo C, Gilli S, et al. Follow-up of sickle cell disease patients with priapism treated by hydroxyurea. Am J Hematol. 2004;77(1):45-49. 74. Anele UA, Kyle Mack A, Resar LM, Burnett AL. Hydroxyurea therapy for priapism prevention and erectile function recovery in sickle cell disease: a case report and review of the literature. Int Urol Nephrol. 2014. 75. Cokic VP, Beleslin-Cokic BB, Tomic M, Stojilkovic SS, Noguchi CT, Schechter AN. Hydroxyurea induces the eNOS-cGMP pathway in endothelial cells. Blood. 2006;108(1):184-191. 76. Gladwin MT, Shelhamer JH, Ognibene FP, et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol. 2002;116(2):436-444. 77. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010;115(26):5300-5311. 78. Danielson CF. The role of red blood cell exchange transfusion in the treatment and prevention of complications of sickle cell disease. Ther Apher. 2002;6(1):24-31. 79. Swerdlow PS. Red cell exchange in sickle cell disease. Hematology Am Soc Hematol Educ Program. 2006:48-53. 80. Merritt AL, Haiman C, Henderson SO. Myth: blood transfusion is effective for sickle cell anemiaassociated priapism. CJEM. 2006;8(2):119-122. 81. Siegel JF, Rich MA, Brock WA. Association of sickle cell disease, priapism, exchange transfusion and neurological events: ASPEN syndrome. J Urol. 1993;150(5 Pt 1):1480-1482. 82. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033-1048. 83. Chung SY, Stein RJ, Cannon TW, Nelson JB. Novel technique in the management of low flow priapism. J Urol. 2003;170(5):1952. 84. Burnett AL, Sharlip ID. Standard operating procedures for priapism. J Sex Med. 2013;10(1):180194. 85. Salonia A, Eardley I, Giuliano F, et al. European Association of Urology guidelines on priapism. Eur Urol. 2014;65(2):480-489. 86. Bodner DR, Lindan R, Leffler E, Kursh ED, Resnick MI. The application of intracavernous injection of vasoactive medications for erection in men with spinal cord injury. J Urol. 1987;138(2):310-311. 87. Lee M, Cannon B, Sharifi R. Chart for preparation of dilutions of alpha-adrenergic agonists for intracavernous use in treatment of priapism. J Urol. 1995;153(4):1182-1183. 88. Muneer A, Minhas S, Freeman A, Kumar P, Ralph DJ. Investigating the effects of high-dose phenylephrine in the management of prolonged ischaemic priapism. J Sex Med. 2008;5(9):2152-2159. 89. Munarriz R, Wen CC, McAuley I, Goldstein I, Traish A, Kim N. Management of ischemic priapism with high-dose intracavernosal phenylephrine: from bench to bedside. J Sex Med. 2006;3(5):918-922. 18

From www.bloodjournal.org by guest on April 13, 2015. For personal use only.

90. Zacharakis E, Raheem AA, Freeman A, et al. The efficacy of the T-shunt procedure and intracavernous tunneling (snake maneuver) for refractory ischemic priapism. J Urol. 2014;191(1):164168. 91. Burnett AL, Pierorazio PM. Corporal "snake" maneuver: corporoglanular shunt surgical modification for ischemic priapism. J Sex Med. 2009;6(4):1171-1176. 92. Segal RL, Readal N, Pierorazio PM, Burnett AL, Bivalacqua TJ. Corporal Burnett "Snake" surgical maneuver for the treatment of ischemic priapism: long-term followup. J Urol. 2013;189(3):1025-1029. 93. Winter CC. Cure of idiopathic priapism: new procedure for creating fistula between glans penis and corpora cavernosa. Urology. 1976;8(4):389-391. 94. Ebbehoj J. A new operation for priapism. Scand J Plast Reconstr Surg. 1974;8(3):241-242. 95. Lue TF, Pescatori ES. Distal cavernosum-glans shunts for ischemic priapism. J Sex Med. 2006;3(4):749-752. 96. Brant WO, Garcia MM, Bella AJ, Chi T, Lue TF. T-shaped shunt and intracavernous tunneling for prolonged ischemic priapism. J Urol. 2009;181(4):1699-1705. 97. Quackels R. [Treatment of a Case of Priapism by Cavernospongious Anastomosis]. Acta Urol Belg. 1964;32:5-13. 98. Sacher EC, Sayegh E, Frensilli F, Crum P, Akers R. Cavernospongiosum shunt in the treatment of priapism. J Urol. 1972;108(1):97-100. 99. Resnick MI, Holland JM, King LR, Grayhack JT. Priapism in boys. Management with cavernosaphenous shunt. Urology. 1975;5(4):492-495. 100. Burnett AL. Surgical management of ischemic priapism. J Sex Med. 2012;9(1):114-120. 101. Rodriguez J, Cuadrado JM, Frances A, Franco E. High-flow priapism as a complication of a venoocclusive priapism: two case reports. Int J Impot Res. 2006;18(2):215-217. 102. Bertolotto M, Ciampalini S, Martingano P, Mucelli FP. High-flow priapism complicating ischemic priapism following iatrogenic laceration of the dorsal artery during a Winter procedure. J Clin Ultrasound. 2009;37(1):61-64. 103. Levey HR, Segal RL, Bivalacqua TJ. Management of priapism: an update for clinicians. Ther Adv Urol. 2014;6(6):230-244. 104. Donaldson JF, Rees RW, Steinbrecher HA. Priapism in children: a comprehensive review and clinical guideline. J Pediatr Urol. 2014;10(1):11-24. 105. Fu S, Tar MT, Melman A, Davies KP. Opiorphin is a master regulator of the hypoxic response in corporal smooth muscle cells. FASEB J. 2014;28(8):3633-3644. 106. Kanika ND, Melman A, Davies KP. Experimental priapism is associated with increased oxidative stress and activation of protein degradation pathways in corporal tissue. Int J Impot Res. 2010;22(6):363373. 107. Bivalacqua TJ, Musicki B, Hsu LL, Berkowitz DE, Champion HC, Burnett AL. Sildenafil citraterestored eNOS and PDE5 regulation in sickle cell mouse penis prevents priapism via control of oxidative/nitrosative stress. PLoS One. 2013;8(7):e68028. 108. Lagoda G, Sezen SF, Hurt KJ, Cabrini MR, Mohanty DK, Burnett AL. Sustained nitric oxide (NO)releasing compound reverses dysregulated NO signal transduction in priapism. FASEB J. 2014;28(1):7684. 109. Wen J, Jiang X, Dai Y, et al. Adenosine deaminase enzyme therapy prevents and reverses the heightened cavernosal relaxation in priapism. J Sex Med. 2010;7(9):3011-3022. 110. Ning C, Wen J, Zhang Y, et al. Excess adenosine A2B receptor signaling contributes to priapism through HIF-1alpha mediated reduction of PDE5 gene expression. FASEB J. 2014;28(6):2725-2735. 111. Burnett AL. Sexual health outcomes improvement in sickle cell disease: a matter of health policy? J Sex Med. 2012;9(1):104-113. 19

From www.bloodjournal.org by guest on April 13, 2015. For personal use only.

Table 1 Causes of priapism Etiology

Examples

Sickle cell disease, thalassemia, glucose-6phosphate dehydrogenase

Hematologic disorders

Vasoactive erectile agents (papaverine, phentolamine, prostaglandin E1, combination therapy) Alpha-adrenergic receptor antagonists (prazosin, terazosin, tamulosin) anti-anxiety agents (hydroxyzine), anti-coagulants (heparin, warfarin), anti-depressants and antipsychotics (trazadone, bupropion, fluoxetine, sertraline, lithium, clozapine, risperidone, olanzapine, chlorpromazine, thioridazine, phenothiazines, anti-hypertensives (hydralazine, guanethidine, propranolol)

Medications

Alcohol, cocaine, marijuana

Recreational Drugs

Gonadotropin-releasing hormone, testosterone

Hormones

Infectious

Scorpion sting, spider bite, rabies, malaria

Metabolic

Amyloidosis, Fabry disease, gout Kidney, bladder, prostate, urethra, penis, testis, colorectal, lung

Neoplastic (regional infiltration or metastatic)

Syphilis, spinal cord injury, cauda equina syndrome, autonomic neuropathy, lumbar disc herniation, spinal stenosis, stroke, brain tumor, spinal anesthesia

Neurogenic

General anxiety disorder, obsessivecompulsive disorder, post-traumatic stress disorder, panic disorder

Anxiety Disorders

General or regional

Anesthesia

Straddle injury, coital injury, pelvic trauma, intracavernous injection needle injury

Trauma (Non-Ischemic)

Penile revascularization surgery, intracavernous needle injury, shunt surgery

Iatrogenic (Non-Ischemic)

20

From www.bloodjournal.org by guest on April 13, 2015. For personal use only.

Prepublished online March 25, 2015; doi:10.1182/blood-2014-09-551887

How I treat priapism Uzoma A. Anele, Brian V. Le, Linda M.S. Resar and Arthur L. Burnett

Information about reproducing this article in parts or in its entirety may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests Information about ordering reprints may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#reprints Information about subscriptions and ASH membership may be found online at: http://www.bloodjournal.org/site/subscriptions/index.xhtml

Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include digital object identifier (DOIs) and date of initial publication.

Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036. Copyright 2011 by The American Society of Hematology; all rights reserved.

How I treat priapism.

Priapism is a disorder of persistent penile erection unrelated to sexual interest or desire. This pathologic condition, specifically the ischemic vari...
659KB Sizes 2 Downloads 14 Views

Recommend Documents


How I treat myelofibrosis.
Myelofibrosis (MF) is a BCR-ABL1-negative myeloproliferative neoplasm characterized by clonal myeloproliferation, dysregulated kinase signaling, and release of abnormal cytokines. In recent years, important progress has been made in the knowledge of

How I treat postpartum hemorrhage.
Worldwide, ∼800 women die every day from preventable causes related to pregnancy or childbirth. The single most common cause is severe bleeding, which can kill a healthy woman within hours if care is substandard or delayed. Improved antenatal practic

How I treat hypereosinophilic syndromes.
Hypereosinophilic syndromes (HESs) are a group of rare disorders characterized by peripheral blood eosinophilia of 1.5 × 10(9)/L or higher and evidence of end organ manifestations attributable to the eosinophilia and not otherwise explained in the cl

How I treat polycythemia vera.
Polycythemia vera (PV) is a chronic myeloproliferative neoplasm associated with JAK2 mutations (V617F or exon 12) in almost all cases. The World Health Organization has defined the criteria for diagnosis, but it is still unclear which parameter (hemo

How I treat mixed-phenotype acute leukemia.
Mixed-phenotype acute leukemia (MPAL) encompasses a heterogeneous group of rare leukemias in which assigning a single lineage of origin is not possible. A variety of different terms and classification systems have been used historically to describe t

How I treat Langerhans cell histiocytosis.
"Langerhans cell histiocytosis" (LCH) describes a spectrum of clinical presentations ranging from a single bone lesion or trivial skin rash to an explosive disseminated disease. Regardless of clinical severity, LCH lesions share the common histology

How I treat splanchnic vein thrombosis.
Antithrombotic treatment of splanchnic vein thrombosis (SVT) is a clinical challenge. Depending on the site of thrombosis, patients are at risk of developing liver insufficiency, portal hypertension, or bowel infarction and may experience recurrence

How I treat first relapse of myeloma.
The standard treatment of relapsed multiple myeloma has been either lenalidomide-dexamethasone (RD) or bortezomib-dexamethasone (VD) but it is changing rapidly for 2 reasons. First, lenalidomide and bortezomib are currently used in frontline treatmen

How I treat advanced classical Hodgkin lymphoma.
The development of curative systemic treatment of Hodgkin lymphoma was recently voted one of the top 5 achievements of oncology in the last 50 years (http://cancerprogress.net/top-5-advances-modern-oncology). The high expectation of cure (above 80%)

How I treat refractory thrombotic thrombocytopenic purpura.
Acquired thrombotic thrombocytopenic purpura (TTP) is characterized by thrombocytopenia and microangiopathic hemolytic anemia (MAHA) without an obvious cause, and may include fever, mild renal failure, and neurologic deficits. It is characterized by